PuriBlood Medical Co (ROCO:6847) Research & Development: NT$33.47 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6847 PuriBlood Medical Co Ltd ROCO:6847
74 GF Score
Price NT$77.70
GF Value NT$66.17
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is PuriBlood Medical Co Research & Development?

PuriBlood Medical Co ROCO:6847 +2.91% 74 Research & Development is NT$33.47 Mil as of Dec. 2025. GuruFocus rates ROCO:6847 with a GF Score™ of 74/100 and a GF Value™ of NT$66.17 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PuriBlood Medical Co's Research & Development for the six months ended in Dec. 2025 was NT$20.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$33.47 Mil.

PuriBlood Medical Co  (ROCO:6847) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PuriBlood Medical Co Research & Development Related Terms

PuriBlood Medical Co Research & Development Historical Data

* Premium members only.

The historical data trend for PuriBlood Medical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PuriBlood Medical Co Research & Development Chart

PuriBlood Medical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 20.77 22.44 25.95 31.23 33.47

PuriBlood Medical Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.61 13.99 17.24 13.40 20.07
ROCO:6847
74GF Score
PuriBlood Medical Co Ltd ROCO:6847
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PuriBlood Medical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$33.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$33.47 Mil mean?
PuriBlood Medical Co (ROCO:6847) has a Research & Development of NT$33.47 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on PuriBlood Medical Co and its competitors.
Is PuriBlood Medical Co's Research & Development too high?
PuriBlood Medical Co's current Research & Development is NT$33.47 Mil. Overall, PuriBlood Medical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Research & Development compare to TMO and DHR?
PuriBlood Medical Co's Research & Development of NT$33.47 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PuriBlood Medical Co and its competitors. PuriBlood Medical Co's current Research & Development is NT$33.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$66.17, compared to a current price of NT$77.70 — trading 17.4% above its estimated fair value. The current Research & Development is NT$33.47 Mil. PuriBlood Medical Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Research & Development is NT$33.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?

Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued. The current stock price of NT$77.70 is trading 17.4% above its estimated GF Value™ of NT$66.17. GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.

Key valuation signals for ROCO:6847:

  • Research & Development: NT$33.47 Mil
  • GF Value™: NT$66.17 vs. price of NT$77.70 (17.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PuriBlood Medical Co Business Description

Address Gongye E. 9th Road, Baoshan Township, 2nd Floor, No.11, Hsinchu County, Baoshan, TWN
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
74GF Score

Get the complete analysis for ROCO:6847

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.70
Price
NT$66.17
GF Value